T he efficacy of an intervention can be defined as the performance under ideal and controlled circumstances, whereas effectiveness refers to its performance under "real-world" conditions. Randomized clinical trials (RCTs) provide the strongest empirical evidence of a treatment's efficacy and safety because they allow for the analysis of a homogenous study population. The generalizability of RCTs, however, is compromised due to the use of strict inclusion and exclusion criteria in selecting participants.
On the other hand, propensity matching has the advantage to identify independent risk factors. In randomized trials comparing TAVR and SAVR, female subjects had lower mortality with TAVR (7), whereas in the current propensity-matched analysis, there were no significant differences in treatment effect across the male/female subgroups. This outlines the fact that not sex in itself, but rather sex-related comorbidities play a role in a better outcome of TAVR in female patients.
The database here is essentially of an administra- 
